ANIX - CIK 0000715446
The table below shows Anixa Biosciences Inc's cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$7.17M | -$7.33M | -$6.21M | -$6.49M | -$4.94M | -$6.18M |
| Capital expenditure | - | - | - | - | - | $15.79K |
| Investing cash flow | $4.87M | $4.28M | -$5.60M | -$10.73M | -$3.92M | -$305.79K |
| Dividends paid | - | - | - | - | - |
Anixa Biosciences Inc reported operating cash flow of -$7.17M for fiscal year 2025. That is up 2.2% from -$7.33M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$3.38M (FY 2016) to -$7.17M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| Stock buybacks | - | $6.00K | - | - | - | - |
| Financing cash flow | $2.28M | $3.42M | $366.00K | $452.00K | $31.57M | $9.41M |